<DOC>
	<DOCNO>NCT02142556</DOCNO>
	<brief_summary>Purpose To evaluate efficacy safety once-daily quetiapine extend release ( XR ) patient schizophrenia switch antipsychotic suboptimal due insufficient efficacy insufficient tolerability . Methods : This 12-week , open-label study conduct Chinese population Taiwan . Quetiapine XR administrate 300 mg day 1 , 600 mg day 2 800 mg day 2 . From day 8 end study , dose quetiapine XR adjust within 400-800 mg per day , depend clinical response tolerability patient .</brief_summary>
	<brief_title>The Efficacy Safety Quetiapine XR Patients With Schizophrenia Switched From Other Antipsychotics</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>The participant age 20 65 year meet diagnosis schizophrenia accord Diagnostic Statistical Manual Mental Disorders , fourth edition , text revision ( DSMIVTR ) eligible recruitment clinical trial . They also fulfil criterion include score 4 ( moderate ) great 7 item Positive Negative Syndrome Scale ( PANSS ) Positive Symptom Subscale need switch previous antipsychotic due insufficient efficacy insufficient tolerability . Any DSMIVTR Axis I disorder schizophrenia , except comorbid obsessivecompulsive disorder , anxiety disorder , eat disorder impulse control disorder stable primary focus treatment previous 6 month An imminent risk suicide danger self others Pregnancy lactation Intolerance lack response quetiapine IR Use cytochrome P450 3A4 inhibitor inducer 14 day precede enrolment Administration depot antipsychotic injection within one dose interval recruitment Unstable inadequately treat medical illness judge investigator .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>